Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Jean Francois Marier"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 10, Pp 1283-1293 (2022)
Abstract The current tutorial describes why forest plots are needed for an effective communication of covariates effects, how they are constructed, and how they should be presented. Simulation‐based methodologies allowing the user to evaluate the m
Externí odkaz:
https://doaj.org/article/c83b89f55cf64660b1be3521588802b9
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2497-2509 (2021)
Abstract Teduglutide is a recombinant analog of human glucagon‐like peptide‐2 that regulates the functional and structural integrity of the cells lining the gastrointestinal tract. Teduglutide is approved for the treatment of patients with short
Externí odkaz:
https://doaj.org/article/e1ad778fc0454aba88a07040677a1f2e
Autor:
Chao, Li, Benjamin, Rich, Julie M, Bullock, Olivier, Barrière, Jean-Francois, Marier, Andrew, Beelen
Publikováno v:
British Journal of Clinical Pharmacology. 89:1067-1079
Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4/6 inhibitor that provides multilineage protection from chemotherapy-induced myelosuppression. This analysis aimed to characterize the population pharmacokinetics (PK) of trilacicl
Autor:
Varun Goel, Xiaoping Zhang, Gabriel J. Robbie, Jean-Francois Marier, Claudia Jomphe, Nathalie H. Gosselin
Publikováno v:
Nucleic Acid Therapeutics. 30:143-152
Hereditary transthyretin-mediated amyloidosis is an inherited, rapidly progressive, life-threatening disease caused by mutated transthyretin (TTR) protein. Patisiran is a small interfering RNA (siRNA) formulated in a lipid nanoparticle that inhibits
Autor:
Grygoriy Vasilinin, Indranil Bhattacharya, Gülden Özen, Jean Francois Marier, Yi Wang, Olivier Barriere, Bjorn Mellgard
Publikováno v:
Blood. 138:2104-2104
Background: rVWF (vonicog alfa; Vonvendi ®,Baxalta US Inc, a Takeda company, Lexington, MA, USA) is a purified recombinant VWF concentrate approved for on-demand (OD) treatment of hemorrhage and management of surgical bleeding in adults with VWD. Th
Autor:
Frank W.G. Leebeek, Giancarlo Castaman, Jean François Marier, Gülden Özen, Indranil Bhattacharya, Jingmei Zhang, Scarlett Wang, Yi Wang
Publikováno v:
TH Open, Vol 08, Iss 02, Pp e243-e251 (2024)
Background Recombinant von Willebrand factor (rVWF, vonicog alfa, Takeda Pharmaceuticals USA) is indicated in adults diagnosed with von Willebrand disease (VWD). In this study, the exposure–response (ER) relationship between VWF activity (VWF:RCo)
Externí odkaz:
https://doaj.org/article/70755f93063a43f19d890e4d1224931f
Autor:
Jean-Francois Marier, R. E. Martell, S. Ropert, M. Beliveau, José Baselga, D. De Andreis, E. Lopez, J-C. Soria, J.P. Armand, A. Catteau, Javier Cortes, J. James, Christophe Massard
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(6)
Purpose We studied the safety, tolerability, and recommended dose of BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases. Patients and methods Patients with advanced sol
Autor:
Katie Zomorodi, Paola Tocchetti, Thomas C. Marbury, Elena Tudone, Jean Francois Marier, Mark Eller
Publikováno v:
Drug Design, Development and Therapy
Paola Tocchetti,1 Elena Tudone,2 Jean-Francois Marier,3 Thomas C Marbury,4 Katie Zomorodi,5 Mark Eller6 1Gentium, 2Clinical Operations, Gentium, Villa Guardia, Como, Italy; 3Reporting and Analysis Services, Pharsight, a Certara Company, Montreal, Que
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:AB103
Publikováno v:
Therapeutic innovationregulatory science. 47(5)
Trial simulations have emerged as a promising tool to optimize pediatric drug development programs. As the current FDA legislation on pediatric drugs and devices was updated to mirror the EMA legislation, pediatric programs must be developed with glo